continuous production of anesthetic …

| |

The Rhine chemist Bachem plans to invest 1 million francs in the expansion of its propofol production capacity. Faced with exceptional demand for this anesthetic, fueled by the treatment of “Covid-19 patients”, the group has already introduced a continuous production rate at its Vionnaz site in Valais.

“Even if propofol – as a small molecule – is not part of our core business, Bachem will continue to offer this active substance (…) from Switzerland in the future”, assures the general manager of the peptide specialist , Thomas Meier, cited in the press release.

Bachem claims to be the leading producer of propofol worldwide.

Previous

Hornets forced to counterattack

A bat valued for its meat is a real health risk

Next

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.